We interrogated a published serum proteomics dataset from the UK-PBC patient cohort33, comparing the levels of ACE2 in the serum of patients who had not been treated with UDCA (n = 62) and patients who had received UDCA (n = 308). The gene discussed is ACE2; the disease is primary biliary cholangitis.